lomefloxacin has been researched along with Urinary Tract Infections in 34 studies
lomefloxacin: structure given in first source
lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of lomefloxacin 400 mg daily in the treatment of complicated urinary tract infections were confirmed in a randomized multicenter study that enrolled 294 patients from 16 centers in Italy." | 9.08 | Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study. ( Bartoletti, R; Pisani, E; Rizzo, M; Trinchieri, A, 1996) |
| "The efficacy of lomefloxacin given at 400 mg once daily for 14 days compared with that of trimethoprim-sulfamethoxazole at 160 and 800 mg, respectively, given twice daily for 14 days in the treatment of symptomatic complicated urinary tract infections was studied in a prospective, randomized, single-blind multicenter study." | 9.07 | Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. ( Dubois, J; Harding, GK; Louie, TJ; Martel, A; Nicolle, LE; Sinave, CP, 1994) |
| "Between April and October 1990, photosensitivity reactions were observed in 19 out of 338 patients who were administered lomefloxacin (LFLX) for the treatment of urinary tract infections (UTI) in our hospital." | 9.07 | [A clinical study of lomefloxacin on the patients with urinary tract infections--focused on lomefloxacin-induced photosensitivity reaction]. ( Honma, H; Kang, K; Tozawa, K; Washida, H; Yamada, Y, 1993) |
| "The bacteriologic and clinical efficacies of 3 days of lomefloxacin therapy were compared with those of 3 days of norfloxacin therapy for the treatment of acute uncomplicated urinary tract infections in a prospective, randomized, double-blind study." | 9.07 | Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. ( Conly, JM; DuBois, J; Harding, GK; Martel, AY; Nicolle, LE; Shafran, SD, 1993) |
| "Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days." | 9.07 | Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections. ( Benne, RA; Boon, TA; de Hond, HA; de Wit, MA; Havinga, WH; Hoepelman, IM; van Asbeck, FW; Verhoef, J; Visser, MR; Zwinkels, M, 1993) |
| "Lomefloxacin, a new difluorinated quinolone, and trimethoprim/sulfamethoxazole (TMP/SMX) were compared in the treatment of adults with uncomplicated urinary tract infections." | 9.07 | Comparison of the safety and efficacy of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infections: results from a multicenter study. ( Aguirre-Avalos, G; Andrade-Villanueva, J; Flores-Gaxiola, A; Lopez-Guillen, P; Morfin-Otero, R; Rodriguez-Noriega, E, 1992) |
| "The efficacy and safety of 7-10-day courses of lomefloxacin (single daily dose of 400 mg) or norfloxacin (twice-daily doses of 400 mg) for the treatment of uncomplicated urinary tract infections were compared in two large, multicenter, randomized trials." | 9.07 | Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. ( Iravani, A, 1992) |
| "The efficacy and safety of two fluoroquinolone antimicrobial agents, lomefloxacin and ciprofloxacin, were compared in a randomized, investigator-blinded, multiple-dose study that enrolled 150 adult outpatients with complicated or recurrent urinary tract infections." | 9.07 | A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. ( Cox, CE, 1992) |
| "Data were collected from 14 French centres which participated in a randomized study to compare the safety and efficacy of 400 mg lomefloxacin taken orally once daily by 62 patients with 160/800 mg trimethoprim/sulphamethoxazole (TMP/SMX) taken orally twice daily by 64 patients with uncomplicated urinary tract infections." | 9.07 | Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxazole. ( Capron, MH; Guibert, J, 1992) |
| "This randomised, double-blind, multicenter study compared the safety and efficacy of lomefloxacin and norfloxacin in adult female outpatients with uncomplicated urinary tract infections." | 9.07 | Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group. ( Forsgren, A; Hansson, C; Neringer, R; Ode, B, 1992) |
| "Lomefloxacin has the economic advantage of an oral route of administration compared to the parenteral route of cefotaxime for prophylaxis in transurethral genitourinary procedures." | 6.67 | Prevention of urinary tract infection and bacteremia following transurethral surgery: oral lomefloxacin compared to parenteral cefotaxime. ( Berger, NS; Crawford, ED; Davis, MA; Donohue, RE, 1992) |
| "The efficacy and safety of lomefloxacin 400 mg daily in the treatment of complicated urinary tract infections were confirmed in a randomized multicenter study that enrolled 294 patients from 16 centers in Italy." | 5.08 | Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study. ( Bartoletti, R; Pisani, E; Rizzo, M; Trinchieri, A, 1996) |
| "The efficacy and safety of levofloxacin and lomefloxacin in complicated urinary tract infections (UTIs) were compared in a randomized, open-label, multicenter study." | 5.08 | A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. ( Callery-D'Amico, S; Cox, CE; Fowler, CL; Kim, SS; King, W; Klimberg, IW, 1998) |
| "The efficacy of lomefloxacin given at 400 mg once daily for 14 days compared with that of trimethoprim-sulfamethoxazole at 160 and 800 mg, respectively, given twice daily for 14 days in the treatment of symptomatic complicated urinary tract infections was studied in a prospective, randomized, single-blind multicenter study." | 5.07 | Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. ( Dubois, J; Harding, GK; Louie, TJ; Martel, A; Nicolle, LE; Sinave, CP, 1994) |
| "Between April and October 1990, photosensitivity reactions were observed in 19 out of 338 patients who were administered lomefloxacin (LFLX) for the treatment of urinary tract infections (UTI) in our hospital." | 5.07 | [A clinical study of lomefloxacin on the patients with urinary tract infections--focused on lomefloxacin-induced photosensitivity reaction]. ( Honma, H; Kang, K; Tozawa, K; Washida, H; Yamada, Y, 1993) |
| "The bacteriologic and clinical efficacies of 3 days of lomefloxacin therapy were compared with those of 3 days of norfloxacin therapy for the treatment of acute uncomplicated urinary tract infections in a prospective, randomized, double-blind study." | 5.07 | Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. ( Conly, JM; DuBois, J; Harding, GK; Martel, AY; Nicolle, LE; Shafran, SD, 1993) |
| "Seventy patients with complicated urinary tract infections were treated with either lomefloxacin (400 mg once daily) or norfloxacin (400 mg twice daily) for 10 to 14 days." | 5.07 | Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections. ( Benne, RA; Boon, TA; de Hond, HA; de Wit, MA; Havinga, WH; Hoepelman, IM; van Asbeck, FW; Verhoef, J; Visser, MR; Zwinkels, M, 1993) |
| "Lomefloxacin, a new difluorinated quinolone, and trimethoprim/sulfamethoxazole (TMP/SMX) were compared in the treatment of adults with uncomplicated urinary tract infections." | 5.07 | Comparison of the safety and efficacy of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infections: results from a multicenter study. ( Aguirre-Avalos, G; Andrade-Villanueva, J; Flores-Gaxiola, A; Lopez-Guillen, P; Morfin-Otero, R; Rodriguez-Noriega, E, 1992) |
| "The efficacy and safety of 7-10-day courses of lomefloxacin (single daily dose of 400 mg) or norfloxacin (twice-daily doses of 400 mg) for the treatment of uncomplicated urinary tract infections were compared in two large, multicenter, randomized trials." | 5.07 | Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults. ( Iravani, A, 1992) |
| "The efficacy and safety of two fluoroquinolone antimicrobial agents, lomefloxacin and ciprofloxacin, were compared in a randomized, investigator-blinded, multiple-dose study that enrolled 150 adult outpatients with complicated or recurrent urinary tract infections." | 5.07 | A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. ( Cox, CE, 1992) |
| "Data were collected from 14 French centres which participated in a randomized study to compare the safety and efficacy of 400 mg lomefloxacin taken orally once daily by 62 patients with 160/800 mg trimethoprim/sulphamethoxazole (TMP/SMX) taken orally twice daily by 64 patients with uncomplicated urinary tract infections." | 5.07 | Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxazole. ( Capron, MH; Guibert, J, 1992) |
| "This randomised, double-blind, multicenter study compared the safety and efficacy of lomefloxacin and norfloxacin in adult female outpatients with uncomplicated urinary tract infections." | 5.07 | Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group. ( Forsgren, A; Hansson, C; Neringer, R; Ode, B, 1992) |
| "Results of trials of lomefloxacin (400 mg once daily) in elderly patients with uncomplicated urinary tract infections, complicated urinary tract infections, acute bacterial exacerbations of chronic bronchitis, and as prophylaxis for transurethral surgical procedures (400 mg single dose) have been analyzed." | 4.78 | Infection in the elderly: studies with lomefloxacin. ( Bruce-Jones, P; Crome, P, 1992) |
| "Eleven elderly patients (mean age 83 years; range 75-90) with microbiologically proven urinary tract infections were given 400 mg lomefloxacin as a single daily dose for up to seven days." | 3.68 | The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg. ( Cowling, P; Lovering, AM; MacGowan, AP; McMullin, CM; Reeves, DS; Rogers, S; White, LO, 1991) |
| "The therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 was compared in alloxan-induced diabetic mice with experimental respiratory and urinary tract infections." | 3.67 | Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. ( Nishino, T; Obana, Y, 1988) |
| " Both fleroxacin and lomefloxacin were given orally, the dosage was 200 mg every 12 hours or 400 mg every 24 hours for 7-14 days." | 2.68 | [A clinical study in the treatment of acute bacterial infections with fleroxacin]. ( Cui, H; Hou, J; Li, J, 1996) |
| "Lomefloxacin was successful in preventing post operative infections in 204 of 207 evaluable patients (98." | 2.67 | A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery. ( Childs, SJ; Klimberg, IW; Klimberg, SR; Madore, RJ, 1992) |
| "Lomefloxacin has the economic advantage of an oral route of administration compared to the parenteral route of cefotaxime for prophylaxis in transurethral genitourinary procedures." | 2.67 | Prevention of urinary tract infection and bacteremia following transurethral surgery: oral lomefloxacin compared to parenteral cefotaxime. ( Berger, NS; Crawford, ED; Davis, MA; Donohue, RE, 1992) |
| " Many of the fluoroquinolone agents have once-daily dosing regimens, enhancing patient adherence." | 2.41 | The expanding role of fluoroquinolones. ( Schaeffer, AJ, 2002) |
| " It is usually administered orally and is well absorbed after oral ingestion." | 2.40 | [Urinary tract infections: risk factors and therapeutic trends]. ( Astorri, AL; Margariti, PA; Mastromarino, C, 1997) |
| "Lomefloxacin is a new fluoroquinolone antimicrobial agent that has undergone extensive worldwide clinical evaluation." | 2.38 | The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone. ( Rizk, E, 1992) |
| " Some of the more resistant strains of Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and Pseudomonas aeruginosa were studied in a dynamic in-vitro model in order to study dosing strategies." | 1.28 | Antimicrobial effects of lomefloxacin in vitro. ( Begg, EJ; Boswell, DR; Chambers, ST; Peddie, BA; Robson, RA, 1991) |
| " The mean elimination half-life from serum was 7 h." | 1.27 | Pharmacokinetics and tissue penetration of orally administered lomefloxacin. ( Andrews, JM; Ashby, JP; Griggs, D; Stone, JW; Wise, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (11.76) | 18.7374 |
| 1990's | 27 (79.41) | 18.2507 |
| 2000's | 3 (8.82) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schaeffer, AJ | 1 |
| Naber, KG | 2 |
| Azadian, BS | 1 |
| Talboys, CA | 1 |
| Roberts, AP | 1 |
| Feinberg, SS | 1 |
| Savitskaia, KI | 1 |
| Trapeznikova, MF | 1 |
| Nekhorosheva, AG | 1 |
| Solodilova, OE | 1 |
| Nasonov, VN | 1 |
| Dutov, VV | 1 |
| Kalinin, VN | 1 |
| Shanina, AG | 1 |
| Rusanova, EV | 1 |
| Nicolle, LE | 2 |
| Louie, TJ | 1 |
| Dubois, J | 2 |
| Martel, A | 1 |
| Harding, GK | 2 |
| Sinave, CP | 1 |
| Tozawa, K | 1 |
| Washida, H | 1 |
| Honma, H | 1 |
| Kang, K | 1 |
| Yamada, Y | 1 |
| Martel, AY | 1 |
| Shafran, SD | 1 |
| Conly, JM | 1 |
| Hoepelman, IM | 1 |
| Havinga, WH | 1 |
| Benne, RA | 1 |
| Zwinkels, M | 1 |
| de Wit, MA | 1 |
| de Hond, HA | 1 |
| Boon, TA | 1 |
| Visser, MR | 1 |
| van Asbeck, FW | 1 |
| Verhoef, J | 1 |
| Spivey, IM | 1 |
| Pisani, E | 1 |
| Bartoletti, R | 1 |
| Trinchieri, A | 1 |
| Rizzo, M | 1 |
| Guibert, J | 2 |
| Herman, H | 1 |
| Capron, MH | 2 |
| Suzuki, T | 1 |
| Sasada, M | 1 |
| Okuma, M | 1 |
| Fukuhara, S | 1 |
| Yasuda, N | 1 |
| Amano, H | 1 |
| Kanachi, K | 1 |
| Ohno, T | 1 |
| Kawasaki, T | 1 |
| Yumoto, Y | 1 |
| Margariti, PA | 1 |
| Astorri, AL | 1 |
| Mastromarino, C | 1 |
| Klimberg, IW | 2 |
| Cox, CE | 2 |
| Fowler, CL | 1 |
| King, W | 1 |
| Kim, SS | 1 |
| Callery-D'Amico, S | 1 |
| Hou, J | 1 |
| Li, J | 1 |
| Cui, H | 1 |
| Derevianko, II | 1 |
| Khodyreva, LA | 1 |
| Avdoshin, VL | 1 |
| Andriukhin, MI | 1 |
| Gabliia, MIu | 1 |
| Crawford, ED | 1 |
| Berger, NS | 1 |
| Davis, MA | 1 |
| Donohue, RE | 1 |
| Charton, M | 1 |
| Mombet, A | 1 |
| Gattegno, B | 1 |
| Childs, SJ | 1 |
| Madore, RJ | 1 |
| Klimberg, SR | 1 |
| Crome, P | 1 |
| Bruce-Jones, P | 1 |
| Rizk, E | 1 |
| Andrade-Villanueva, J | 1 |
| Flores-Gaxiola, A | 1 |
| Lopez-Guillen, P | 1 |
| Aguirre-Avalos, G | 1 |
| Morfin-Otero, R | 1 |
| Rodriguez-Noriega, E | 1 |
| Iravani, A | 1 |
| Neringer, R | 1 |
| Forsgren, A | 1 |
| Hansson, C | 1 |
| Ode, B | 1 |
| Cowling, P | 1 |
| Rogers, S | 1 |
| McMullin, CM | 1 |
| White, LO | 1 |
| Lovering, AM | 1 |
| MacGowan, AP | 1 |
| Reeves, DS | 1 |
| Chambers, ST | 1 |
| Peddie, BA | 2 |
| Robson, RA | 1 |
| Begg, EJ | 1 |
| Boswell, DR | 1 |
| Stone, JW | 1 |
| Andrews, JM | 1 |
| Ashby, JP | 1 |
| Griggs, D | 1 |
| Wise, R | 1 |
| Obana, Y | 1 |
| Nishino, T | 1 |
5 reviews available for lomefloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
The expanding role of fluoroquinolones.
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Enoxacin; Fluoroquinolones; Ga | 2002 |
Levofloxacin in the treatment of urinary tract infections and prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug | 2004 |
[Urinary tract infections: risk factors and therapeutic trends].
Topics: Anti-Infective Agents; Anti-Infective Agents, Urinary; Female; Fluoroquinolones; Humans; Male; Quino | 1997 |
Infection in the elderly: studies with lomefloxacin.
Topics: Aged; Aging; Anti-Infective Agents; Bacterial Infections; Bronchitis; Female; Fluoroquinolones; Huma | 1992 |
The U.S. clinical experience with lomefloxacin, a new once-daily fluoroquinolone.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Fluoroquinolones; Humans; Meta-Analysis as | 1992 |
20 trials available for lomefloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Fluoroquinolones | 2002 |
[Maxaquin and ciprofloxacin in the treatment of complicated and recurrent urinary infections in adults].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Humans; Mal | 1994 |
Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Fluoroquinolones; Humans; Male; Middl | 1994 |
[A clinical study of lomefloxacin on the patients with urinary tract infections--focused on lomefloxacin-induced photosensitivity reaction].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; B | 1993 |
Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Canada; Double-Blind Method; Female; | 1993 |
Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Fluoroquinolones; Humans; | 1993 |
Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: a multicenter study.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Female; F | 1996 |
[Treatment of uncomplicated recurrent cystitis in women: lomefloxacin versus norfloxacin].
Topics: Adult; Anti-Infective Agents; Cystitis; Drug Administration Schedule; Female; Fluoroquinolones; Huma | 1997 |
[Clinical efficacy of lomefloxacin for associated infection in patients with hematological diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Female; Flu | 1997 |
A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, Urinary; Female; Fluor | 1998 |
[A clinical study in the treatment of acute bacterial infections with fleroxacin].
Topics: Adult; Anti-Infective Agents; Female; Fleroxacin; Fluoroquinolones; Humans; Male; Middle Aged; Quino | 1996 |
[Efficacy of lomefloxacin in treatment of nonspecific inflammatory diseases and in prophylaxis of postoperative complications in urology].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Female; F | 1998 |
Prevention of urinary tract infection and bacteremia following transurethral surgery: oral lomefloxacin compared to parenteral cefotaxime.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Bacteremia; Cefotaxime; Female; Female Urogenita | 1992 |
Urinary tract infection prophylaxis in transurethral surgery: oral lomefloxacin versus parenteral cefuroxime.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Cefuroxime; Female; Fluoroquinolones; Humans; Inj | 1992 |
A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Cefotaxime; Female; Flu | 1992 |
Comparison of the safety and efficacy of lomefloxacin and trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infections: results from a multicenter study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Female; Flu | 1992 |
Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Administratio | 1992 |
A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; F | 1992 |
Uncomplicated urinary tract infections: lomefloxacin versus trimethoprim/sulphamethoxazole.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Drug Admini | 1992 |
Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Double-Blind Method; Drug Administration Schedule; F | 1992 |
9 other studies available for lomefloxacin and Urinary Tract Infections
| Article | Year |
|---|---|
In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacteria; Enoxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Of | 1989 |
Fluoroquinolone-induced depression.
Topics: Adult; Anti-Infective Agents; Depressive Disorder; Female; Fluoroquinolones; Humans; Quinolones; Sub | 1995 |
Criteria for use of ofloxacin and lomefloxacin in adult inpatients and outpatients.
Topics: Adult; Anti-Infective Agents; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infectio | 1993 |
Two new fluoroquinolones.
Topics: Anti-Infective Agents; Clinical Trials as Topic; Drug Interactions; Fluoroquinolones; Humans; Microb | 1992 |
The pharmacokinetics of lomefloxacin in elderly patients with urinary tract infection following daily dosing with 400 mg.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Drug Administration Schedule; Drug Evaluation; Fluor | 1991 |
Antimicrobial effects of lomefloxacin in vitro.
Topics: 4-Quinolones; Anti-Infective Agents; Bacteria; Chromatography, High Pressure Liquid; Drug Resistance | 1991 |
In vitro sensitivities of urinary tract pathogens to lomefloxacin and five other antimicrobial agents.
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; Fluoroquinolones; Humans; Microbial Sens | 1989 |
Pharmacokinetics and tissue penetration of orally administered lomefloxacin.
Topics: 4-Quinolones; Administration, Oral; Adult; Anti-Infective Agents; Body Fluids; Chromatography, High | 1988 |
Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Diabetes Mellitus, Experimental; Female; Fluoroquinol | 1988 |